Citigroup, Leerink Partners and Wells Fargo are the bookrunners
By Toni Weeks
San Luis Obispo, Calif., Jan. 12 – Five Prime Therapeutics, Inc. said it partially exercised the $11.25 million greenshoe option on its public sale of stock, raising a total of $84,258,768.
The company sold 3,829,944 common shares, including 419,994 shares from the greenshoe, at $22.00 per share. The price per share is a 4.35% discount to the Feb. 5 closing share price of $23.00.
The company had originally offered to sell 3.41 million shares with an additional 511,500 shares comprising the greenshoe.
Citigroup, Leerink Partners and Wells Fargo Securities were the bookrunning managers.
Proceeds will be used for clinical development, research and pre-clinical development activities, working capital and general corporate purposes.
The clinical-stage biotechnology company is based in South San Francisco, Calif.
| Issuer: | Five Prime Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $84,258,768 (includes $9,239,868 from greenshoe)
|
| Shares: | 3,829,944 (including greenshoe of 419,994 shares)
|
| Price: | $22.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup, Leerink Partners and Wells Fargo Securities
|
| Co-managers: | Guggenheim Securities and Oppenheimer & Co.
|
| Pricing date: | Jan. 7
|
| Settlement date: | Jan. 12
|
| Stock exchange: | Nasdaq: FPRX
|
| Stock price: | $23.00 at close Jan. 6
|
| Market capitalization: | $474.78 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
